Raymond James initiated coverage of Cogent Biosciences (COGT) with a Strong Buy rating and $30 price target The firm thinks the company’s lead asset bezuclastinib possesses best-in-class potential in the “large and expanding” non-advanced systemic mastocytosis market. Key opinion leaders believe bezuclastinib possesses a differentiated profile, offering a meaningful efficacy and safety benefit, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences price target raised to $20 from $17 at Guggenheim
- Cogent Biosciences price target lowered to $21 from $22 at H.C. Wainwright
- Cogent Biosciences Reports Increased Losses Amidst Ongoing Development
- Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences
- Cogent Biosciences reports Q2 net loss $73.529M vs $58.95M last year